Ji Hyun Kim, M.D.

Ji Hyun Kim, M.D. is a radiation oncologist at City of Hope | South Bay.

Dr. Kim received her undergraduate degree in biochemistry from the University of California Davis. She went on to earn a Master of Medical Sciences degree followed by her medical doctorate from Drexel University College of Medicine in Philadelphia. She completed an internship in internal medicine at the University of Nevada School of Medicine in Las Vegas before going on to complete her radiation oncology residency at City of Hope.

Dr. Kim is board certified in radiation oncology, and is a member in good standing with numerous professional societies including the American Society for Clinical Oncology, the American Society for Radiation Oncology and the Radiological Society of North America, to name a few. She has published in the peer-reviewed literature and has been involved with several innovative translational research protocols here at City of Hope.

• Kim JH, Schultheiss TE, Wong JW, Chen YJ. “Stage I and II Endometrial Adenocarcinoma: Analysis of 2009 FIGO Staging Revision and Impact on Survival by Adjuvant Therapy.” Manuscript in preparation for submission to Annals of Oncology (2013).
• Kim JH, Stein A, Rosenthal J, Schultheiss TE, Liu A, Palmer J, Tsai N, Forman S, Kogut N, Wong JY. “Extramedullary (EM) Relapse Following Total Marrow and Lymphoid Irradiation (TMLI) in Patients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT).” Manuscript in preparation for submission to the International Journal of Radiation Oncology Biology Physics (2013).
• Kim JH, Wong P, Shively JE, Wong JY. “64Cu-labeled targeted nanoparticle PET imaging in prostate cancer.” Manuscript in preparation (2013).
• Kim JH, Li L, Quang TS, Emrich JG, Yaeger TE, Jenrette JM, Cohen SC, Black P, Brady LW. “Phase II trial of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of anaplastic astrocytoma.” J of Rad Oncol September 30, 2012 Online first.
• Han CH, Nguyen K, Kim JH, Pezner RD, Schultheiss TE, Wong JY. “Radiobiologic evaluation of lung toxicity in treatment plan quality comparisons for hypofractionated stereotactic body radiotherapy using relative damaged volume modeling.” Med. Phys. 2011; 38(6):i-3908.
• Daugherty LC, Morales S, Fisher B, Li L, Kim J, Quang T, Emrich J, Yaeger T, Komarnicky L, Brady LW. “A phase II study of surgical excision, temozolomide, radiotherapy, and anti-EGFR radioimmunotherapy (EXTRA) as adjuvant therapy in high-grade gliomas.” Int J Radiat Oncol Biol Phys. 2011; 81(2 Suppl):S180.
• Li L, Quang TS, Gracely EJ, Kim JH, Emrich JG, Yaeger TE, Jenrette JM, Cohen SC, Black P, Brady LW. “A phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.” J Neurosurg. 2010; 113(2):192-198.
• Kim JH, Li L, Quang TS, Emrich JG, Yaeger TE, Jenrette JM, Cohen SC, Brady LW. “Anti-EGFR radioimmunotherapy in the treatment of astrocytoma with anaplastic foci (AAF)”. Int J Radiat Oncol Biol Phys. 2008; 72(1 Suppl):S53.
• Kim J, Li L, Quang T, Emrich J, Yaeger T, Jenrette J, Cohen S, Brady L. “Anti-EGFR radioimmunotherapy in the treatment of astrocytoma with anaplastic foci (AAF): a 20 year experience.” Am J Clin Oncol. 2008; 31(6):620-621.
• Li L, Quang TS, Gracely E, Emrich JG, Kim J, Yaeger TE, Jenrette JM, Brady LW. “Glioblastoma multiforme: a 20-year experience using radioimmunotherapy and temozolomide.” Neuro Oncol. 2007; 9(4):508.
• Li L, Quang TS, Gracely EJ, Emrigh JG, Kim J, Yaeger TE, Jenrette JM, Cohen SC, Brady LW. “Radioimmunotherapy and temozolomide in the treatment of glioblastoma multiforme: a 20 year experience.” Int J Radiat Oncol Biol Phys. 2007; 69(3 Suppl):S48.
• Blackwood-Chirchir A, Tretiakova M, Yuan W, Singh Y, Kim J, Das T, Garber J, Klein C, Olopade O, Weber B. “p27 and pAKT Expression in BRCA-1 Associated and Sporadic Breast Tumors.” J Clin Oncol 2004 22(14S):9609.